Immunic presents Phase 2 CALLIPER trial data for vidofludimus calcium at CMSC 2026

Immunic announced presentation of three posters at the CMSC Annual Meeting showcasing additional Phase 2 CALLIPER trial data for vidofludimus calcium in progressive multiple sclerosis, including a late-breaking analysis introducing novel statistical methods for measuring disability changes. The data highlight favorable safety, tolerability, and patient-reported outcomes, supporting continued development of the lead asset for MS treatment.